养心氏片治疗冠状动脉粥样硬化性心脏病心绞痛的快速卫生技术评价

Evaluation of Yangxinshi Tablet in the Treatment of Coronary Heart Disease and Angina Pectoris

目的通过快速评估养心氏片治疗冠状动脉粥样硬化性心脏病心绞痛的有效性、安全性及经济性,为临床用药提供有力的循证依据。方法对PubMed、The Cochrane Library、EMBase、中国期刊全文数据库、万方数据知识服务平台、中文期刊全文数据库和国内外卫生技术评估(health technology assessment,HTA)机构官方网站进行系统检索,纳入养心氏片治疗冠状动脉粥样硬化性心脏病心绞痛的HTA报告、Meta分析以及药物经济学研究,采用定性描述的方法总结所纳入研究的结论,并评估其方法学质量。结果共纳入20篇文献,其中14篇为随机对照试验(RCT),4篇药物经济学研究和2篇系统评价/Meta分析,未检索到相关HTA报告。结果显示:1)养心氏片可降低血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白(LDL)及超敏C反应蛋白(hs-CRP)水平;2)对于冠状动脉粥样硬化性心脏病心绞痛患者,联合应用养心氏片可提高疗效;3)经济学研究表明,养心氏片治疗冠状动脉粥样硬化性心脏病心绞痛患者具有成本-效果优势。结论基于目前可获得的证据支持,养心氏片可用于治疗冠状动脉粥样硬化性心脏病心绞痛。

Objective By rapidly evaluating the effectiveness,safety and economy of Yangxinshi Tablet in the treatment of coronary heart disease and angina pectoris,it provides evidence-based evidence for the rational use of drugs in clinical practice.Methods The official websites of PubMed,The Cochrane Library,Embase,CNKI,Wanfang Database,VIP Database and Health Technology Assessment(HTA)at home and abroad were searched systematically.The HTA report of Yangxinshi Tablet in the treatment of coronary heart disease and angina pectoris,systematic review/meta-analysis(meta-analysis),randomized controlled trial(RCT)and pharmacoeconomic study were included.Qualitative description was used to summarize the conclusions of the included studies and to assess their methodological quality.Results A total of 20 articles were included,14 of which were RCTs,4pharmacoeconomic studies and 2 systematic reviews/Meta analysis.No relevant HTA reports were retrieved.The results showed that:1)Yangxin’s tablets can reduce serum levels of TC,TG,LDL and hs-CRP;2)For patients with coronary heart disease and angina,the combined application of Yangxin’s tablets can improve the efficacy of patients with coronary heart disease and angina;3)Economic research shows that Yangxin’s tablets have cost-effective advantages for patients with coronary heart disease and angina pectoris.Conclusion Based on the currently available evidence,Yangxin’s tablets can be used for the treatment of coronary heart disease and angina pectoris.